Mechanism of action
Lisdexamfetamine is an inactive prodrug consisting of dexamphetamine covalently bound to L-lysine. After oral administration, it is absorbed from the gastrointestinal tract and then enzymatically hydrolyzed in the blood by red blood cell-associated enzymes to yield the active moiety, dexamphetamine, and L-lysine.
Dexamphetamine is a non-catecholamine sympathomimetic amine that acts primarily by:
- Increasing synaptic dopamine and norepinephrine: Dexamphetamine enters presynaptic terminals via dopamine and norepinephrine transporters (DAT and NET) and promotes the release of these neurotransmitters into the synaptic cleft through reverse transport and disruption of vesicular storage via VMAT2 inhibition
- Blocking reuptake: Competitively inhibits DAT and NET, prolonging neurotransmitter action in the synapse
- Weak MAO inhibition: Minimal but contributes to increased cytoplasmic catecholamine availability
The result is enhanced catecholaminergic neurotransmission in the prefrontal cortex and striatum, improving executive function, attention, and impulse control in ADHD. The mechanism in binge eating disorder is less clear but likely involves modulation of reward pathways and appetite regulation in the hypothalamus and mesolimbic system.
The prodrug design confers slower onset and more sustained plasma levels of dexamphetamine compared to immediate-release formulations, theoretically reducing peak-related euphoria and abuse liability.
- Lisdexamfetamine is a prodrug requiring enzymatic hydrolysis in red blood cells to release active dexamphetamine
- Schedule II controlled substance with black box warning for high abuse and dependence potential
- FDA-approved for ADHD (ages ≥6 years) and moderate-to-severe binge eating disorder in adults
- Contraindicated with MAOIs (allow 14-day washout) and in symptomatic cardiovascular disease
- Monitor blood pressure, heart rate, growth (pediatrics), and psychiatric symptoms during therapy
- Adverse effects include decreased appetite, insomnia, cardiovascular events, and growth suppression in children
- Prodrug formulation reduces abuse potential via intranasal/IV routes compared to immediate-release amphetamines
- Alkalinizing agents decrease renal excretion and prolong amphetamine half-life; acidifying agents increase excretion
Indications
Lisdexamfetamine is FDA-approved for:
- Attention-deficit/hyperactivity disorder (ADHD): First-line pharmacotherapy in children aged 6 years and older, adolescents, and adults. Improves core symptoms of inattention, hyperactivity, and impulsivity.
- Moderate-to-severe binge eating disorder (BED): First medication approved for BED in adults. Reduces the number of binge eating days per week.
Off-label uses
While not FDA-approved, lisdexamfetamine is sometimes used off-label for:
- Treatment-resistant depression (as augmentation)
- Narcolepsy and excessive daytime sleepiness (though dexamphetamine itself is preferred)
- Cognitive enhancement in certain neurological conditions
Off-label use should be approached cautiously given the controlled substance status and adverse effect profile.
Pharmacokinetics
Absorption
Rapidly absorbed after oral administration. The prodrug itself has minimal CNS activity. Peak plasma concentration of lisdexamfetamine occurs at approximately 1 hour, but peak dexamphetamine levels occur at 3.5 hours post-dose due to the conversion step.
Distribution
Dexamphetamine is widely distributed throughout the body, including the CNS. Volume of distribution is moderate. Plasma protein binding is low.
Metabolism
Lisdexamfetamine is not metabolized by cytochrome P450 enzymes. Conversion to dexamphetamine occurs via enzymatic hydrolysis in the blood, primarily by red blood cells. Dexamphetamine is then metabolized hepatically by CYP2D6 to inactive metabolites including benzoic acid and hippuric acid.
Excretion
Primarily renal. Approximately 96% of an oral dose is recovered in urine, with about 42% as amphetamine, 25% as hippuric acid, and the remainder as other metabolites. Elimination half-life of dexamphetamine after lisdexamfetamine administration is approximately 10-12 hours.
Special populations
- Renal impairment: Clearance is reduced; dose adjustment required in severe impairment (GFR 15-30 mL/min/1.73m²); avoid in end-stage renal disease
- Hepatic impairment: No dose adjustment needed for conversion step, but monitor for altered dexamphetamine metabolism
- Pediatric: Approved for children ≥6 years; pharmacokinetics similar to adults on a weight-adjusted basis
- Geriatric: Limited data; increased sensitivity to adverse effects expected
Adverse effects
Lisdexamfetamine carries a black box warning for high potential for abuse and dependence. It is a Schedule II controlled substance.
Common adverse effects
- Cardiovascular: Tachycardia, palpitations, hypertension (dose-related increases in heart rate and blood pressure)
- CNS: Insomnia, headache, dizziness, irritability, anxiety, restlessness, dysphoria
- Gastrointestinal: Decreased appetite (very common, dose-limiting), dry mouth, nausea, abdominal pain, weight loss
- Psychiatric: Mood lability, agitation
Serious adverse effects
- Cardiovascular events: Sudden cardiac death in patients with structural cardiac abnormalities, myocardial infarction, stroke, increased risk of serious arrhythmias. Screen for cardiac disease before initiating.
- Psychiatric disturbances: New or worsening psychosis, mania, or bipolar disorder; aggression; suicidal ideation (rare but reported)
- Seizures: May lower seizure threshold
- Peripheral vasculopathy including Raynaud phenomenon: Digital ulceration and soft tissue breakdown reported
- Serotonin syndrome: When combined with serotonergic agents
- Growth suppression: Pediatric patients may experience slowing of growth rate and weight gain; monitor height and weight regularly. Drug holidays may be considered.
- Priapism: Rare but serious; requires immediate medical attention
Withdrawal
Abrupt discontinuation after prolonged use may precipitate severe fatigue, depression, and sleep disturbances.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to amphetamine products or any formulation component
- Use within 14 days of monoamine oxidase inhibitor (MAOI) therapy (risk of hypertensive crisis)
- Symptomatic cardiovascular disease, moderate-to-severe hypertension, advanced arteriosclerosis
- Hyperthyroidism (potentiates sympathomimetic effects)
- Glaucoma (may increase intraocular pressure)
- Agitated states
- History of drug abuse
Warnings and precautions
- Cardiovascular screening: Obtain thorough cardiovascular history, family history, and physical examination. Consider ECG if indicated. Sudden death has occurred in children and adolescents with structural cardiac abnormalities.
- Psychiatric monitoring: Screen for personal or family history of bipolar disorder, psychosis, or suicidal ideation before initiating. Monitor for symptom emergence or worsening.
- Growth monitoring: Plot height and weight on growth charts in pediatric patients. Consider treatment interruption if growth suppression occurs.
- Seizure disorder: Use with caution; may lower seizure threshold.
- Pregnancy: Category C (now classified as no adequate human data). Amphetamines cross the placenta. Neonatal withdrawal and premature delivery reported. Use only if benefit outweighs risk.
- Lactation: Amphetamines are excreted in breast milk. Breastfeeding is not recommended.
- Dependence and abuse: High potential for misuse, abuse, and diversion. Assess risk before prescribing and monitor for signs of misuse.
Drug interactions
Major interactions
- MAOIs (phenelzine, tranylcypromine, selegiline): Contraindicated. Risk of hypertensive crisis. Allow at least 14 days washout.
- Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, linezolid): Increased risk of serotonin syndrome, particularly at high doses.
- Acidifying agents (ammonium chloride, ascorbic acid): Increase renal elimination of amphetamines, reducing efficacy.
- Alkalinizing agents (sodium bicarbonate, acetazolamide, some antacids): Decrease renal elimination, prolonging amphetamine half-life and increasing toxicity risk.
Moderate interactions
- Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensive medications.
- Proton pump inhibitors, H2 antagonists: May alter gastrointestinal pH and absorption, though clinical significance with lisdexamfetamine (which is absorbed and converted in blood) is limited.
- Tricyclic antidepressants: Enhanced cardiovascular effects; monitor closely.
- CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine): May reduce metabolism of dexamphetamine, though conversion from lisdexamfetamine is unaffected.
- Halogenated anesthetics: Risk of sudden increase in blood pressure and arrhythmias; discontinue lisdexamfetamine well before elective surgery.
Mechanism note
Because lisdexamfetamine itself is not metabolized by cytochrome P450 enzymes (conversion is enzymatic in blood), it has fewer drug-drug interactions at the metabolism level compared to other CNS stimulants. However, the active dexamphetamine moiety retains all traditional amphetamine interactions.
Clinical pearls
- Prodrug advantage: The covalent linkage to L-lysine requires enzymatic cleavage, making lisdexamfetamine less amenable to misuse by non-oral routes (intranasal, intravenous). This gives it a theoretically lower abuse potential than immediate-release amphetamines, though it remains Schedule II.
- Once-daily dosing: The pharmacokinetic profile allows for single morning dosing with effects lasting 10-13 hours, improving adherence compared to multiple-daily-dose stimulants.
- Food effect: May be taken with or without food. Unlike some extended-release formulations, food does not significantly alter absorption.
- Capsule administration: Capsules may be opened and dissolved in water for patients unable to swallow; the entire contents must be consumed immediately.
- Binge eating disorder: Lisdexamfetamine is the only FDA-approved medication for BED. Effects are seen within weeks, with reduction in binge days per week.
- Growth monitoring: Pediatric patients should have drug holidays (e.g., summer breaks) considered to allow catch-up growth and reassess need for continued therapy.
- Screening before prescribing: Always assess for cardiovascular risk factors, personal or family psychiatric history, and substance use disorder risk.
- Not a first-line cognitive enhancer: Despite off-label use for cognitive enhancement in healthy individuals, there is no evidence supporting efficacy and significant ethical and safety concerns exist.
- Testing considerations: Urine drug screens will detect amphetamines. Inform patients that lisdexamfetamine will result in a positive amphetamine test.
- Switching from other stimulants: When transitioning from methylphenidate or mixed amphetamine salts, start at the recommended starting dose rather than dose-equivalent conversion, then titrate based on response.
Practice questions
1. A 9-year-old boy with ADHD is started on lisdexamfetamine. His parents call the clinic 2 weeks later reporting that he has difficulty falling asleep and has lost 2 kg. Vital signs show BP 118/76 mmHg (previously 105/65 mmHg) and HR 98 bpm (previously 82 bpm). Which of the following is the most appropriate next step in management?
2. A 28-year-old woman with a history of binge eating disorder has been taking lisdexamfetamine for 8 weeks with good reduction in binge episodes. She now presents to the emergency department with agitation, diaphoresis, tremor, hyperreflexia, and confusion. Temperature is 38.9°C (102°F). She recently started a new medication from her primary care physician. Which of the following medications most likely precipitated this presentation?
3. A 12-year-old girl has been taking lisdexamfetamine for ADHD for 18 months. Growth chart review shows her height has dropped from the 60th percentile to the 25th percentile. Weight remains at the 40th percentile. Parents report good symptom control and improved academic performance. Which of the following is the most appropriate management?
Frequently asked questions
How does lisdexamfetamine work?
Lisdexamfetamine is an inactive prodrug that is enzymatically converted to dexamphetamine in the blood by red blood cell enzymes. Dexamphetamine increases dopamine and norepinephrine release in the brain and blocks their reuptake, enhancing attention, impulse control, and executive function. The prodrug design provides a slower onset and more sustained therapeutic effect compared to immediate-release amphetamines, theoretically reducing abuse potential while maintaining clinical efficacy for ADHD and binge eating disorder.
What are the side effects of lisdexamfetamine?
Common side effects include decreased appetite, dry mouth, insomnia, headache, increased heart rate, and elevated blood pressure. Serious adverse effects include cardiovascular events (sudden cardiac death, myocardial infarction, stroke), new or worsening psychiatric symptoms (psychosis, mania, aggression), growth suppression in children, seizures, peripheral vasculopathy, and serotonin syndrome when combined with serotonergic drugs. It has high abuse and dependence potential as a Schedule II controlled substance. Patients should be monitored for cardiovascular and psychiatric symptoms throughout treatment.
Is lisdexamfetamine a controlled substance?
Yes, lisdexamfetamine is a Schedule II controlled substance in the United States due to its high potential for abuse and dependence. Despite being a prodrug requiring enzymatic conversion to the active form, it retains significant abuse liability. The DEA classification reflects the risk of psychological and physical dependence with prolonged use. Prescribers must assess abuse risk before initiating therapy, use state prescription drug monitoring programs, and monitor patients for signs of misuse or diversion during treatment.
Lisdexamfetamine vs dexamphetamine — what is the difference?
Lisdexamfetamine is a prodrug that must be enzymatically converted to dexamphetamine (the active form) in the blood. This gives lisdexamfetamine a slower onset, longer duration of action (10-13 hours), and once-daily dosing compared to immediate-release dexamphetamine. The prodrug formulation also reduces abuse potential via non-oral routes since intranasal or intravenous use bypasses the enzymatic conversion. Both drugs ultimately work through the same mechanism but differ in pharmacokinetics and abuse liability profile.
Can lisdexamfetamine be used for weight loss?
Lisdexamfetamine is FDA-approved specifically for moderate-to-severe binge eating disorder, not for general weight loss or obesity. While appetite suppression and weight loss are common side effects, using lisdexamfetamine solely for weight reduction is off-label and not recommended due to significant cardiovascular and psychiatric risks, high abuse potential, and lack of evidence supporting efficacy or safety for this indication. Weight loss in binge eating disorder is a secondary benefit to reducing binge episodes, not the primary therapeutic target.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06BA12
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.